178 related articles for article (PubMed ID: 19947776)
1. Cross-platform method for identifying candidate network biomarkers for prostate cancer.
Jin G; Zhou X; Cui K; Zhang XS; Chen L; Wong ST
IET Syst Biol; 2009 Nov; 3(6):505-12. PubMed ID: 19947776
[TBL] [Abstract][Full Text] [Related]
2. A data-analytic strategy for protein biomarker discovery: profiling of high-dimensional proteomic data for cancer detection.
Yasui Y; Pepe M; Thompson ML; Adam BL; Wright GL; Qu Y; Potter JD; Winget M; Thornquist M; Feng Z
Biostatistics; 2003 Jul; 4(3):449-63. PubMed ID: 12925511
[TBL] [Abstract][Full Text] [Related]
3. Novel breast cancer biomarkers identified by integrative proteomic and gene expression mapping.
Ou K; Yu K; Kesuma D; Hooi M; Huang N; Chen W; Lee SY; Goh XP; Tan LK; Liu J; Soon SY; Bin Abdul Rashid S; Putti TC; Jikuya H; Ichikawa T; Nishimura O; Salto-Tellez M; Tan P
J Proteome Res; 2008 Apr; 7(4):1518-28. PubMed ID: 18318472
[TBL] [Abstract][Full Text] [Related]
4. [Proteomic analysis of prostate cancer using surface enhanced laser desorption/ionization mass spectrometry].
Pan YZ; Xiao XY; Zhao D; Zhang L; Ji GY; Li Y; He DC; Zhao XJ; Yang BX
Zhonghua Yi Xue Za Zhi; 2005 Nov; 85(45):3172-5. PubMed ID: 16405834
[TBL] [Abstract][Full Text] [Related]
5. Discovery of prostate cancer biomarkers by microarray gene expression profiling.
Sørensen KD; Ørntoft TF
Expert Rev Mol Diagn; 2010 Jan; 10(1):49-64. PubMed ID: 20014922
[TBL] [Abstract][Full Text] [Related]
6. Simultaneous and exact interval estimates for the contrast of two groups based on an extremely high dimensional variable: application to mass spec data.
Park Y; Downing SR; Kim D; Hahn WC; Li C; Kantoff PW; Wei LJ
Bioinformatics; 2007 Jun; 23(12):1451-8. PubMed ID: 17459967
[TBL] [Abstract][Full Text] [Related]
7. Prostate cancer and the genomic revolution: Advances using microarray analyses.
Calvo A; Gonzalez-Moreno O; Yoon CY; Huh JI; Desai K; Nguyen QT; Green JE
Mutat Res; 2005 Aug; 576(1-2):66-79. PubMed ID: 15950992
[TBL] [Abstract][Full Text] [Related]
8. Prohibitin identified by proteomic analysis of prostate biopsies distinguishes hyperplasia and cancer.
Ummanni R; Junker H; Zimmermann U; Venz S; Teller S; Giebel J; Scharf C; Woenckhaus C; Dombrowski F; Walther R
Cancer Lett; 2008 Aug; 266(2):171-85. PubMed ID: 18384941
[TBL] [Abstract][Full Text] [Related]
9. Dependence network modeling for biomarker identification.
Qiu P; Wang ZJ; Liu KJ; Hu ZZ; Wu CH
Bioinformatics; 2007 Jan; 23(2):198-206. PubMed ID: 17077095
[TBL] [Abstract][Full Text] [Related]
10. The role of tissue microarrays in prostate cancer biomarker discovery.
Datta MW; True LD; Nelson PS; Amin MB
Adv Anat Pathol; 2007 Nov; 14(6):408-18. PubMed ID: 18049130
[TBL] [Abstract][Full Text] [Related]
11. Proteomics for the identification of new prostate cancer biomarkers.
Ornstein DK; Tyson DR
Urol Oncol; 2006; 24(3):231-6. PubMed ID: 16678055
[TBL] [Abstract][Full Text] [Related]
12. A robust meta-classification strategy for cancer detection from MS data.
Bhanot G; Alexe G; Venkataraghavan B; Levine AJ
Proteomics; 2006 Jan; 6(2):592-604. PubMed ID: 16342141
[TBL] [Abstract][Full Text] [Related]
13. Prostate cancer biomarker discovery using high performance mass spectral serum profiling.
Oh JH; Lotan Y; Gurnani P; Rosenblatt KP; Gao J
Comput Methods Programs Biomed; 2009 Oct; 96(1):33-41. PubMed ID: 19423179
[TBL] [Abstract][Full Text] [Related]
14. Integrated pipeline for mass spectrometry-based discovery and confirmation of biomarkers demonstrated in a mouse model of breast cancer.
Whiteaker JR; Zhang H; Zhao L; Wang P; Kelly-Spratt KS; Ivey RG; Piening BD; Feng LC; Kasarda E; Gurley KE; Eng JK; Chodosh LA; Kemp CJ; McIntosh MW; Paulovich AG
J Proteome Res; 2007 Oct; 6(10):3962-75. PubMed ID: 17711321
[TBL] [Abstract][Full Text] [Related]
15. Quantitative proteomic and genomic profiling reveals metastasis-related protein expression patterns in gastric cancer cells.
Chen YR; Juan HF; Huang HC; Huang HH; Lee YJ; Liao MY; Tseng CW; Lin LL; Chen JY; Wang MJ; Chen JH; Chen YJ
J Proteome Res; 2006 Oct; 5(10):2727-42. PubMed ID: 17022644
[TBL] [Abstract][Full Text] [Related]
16. Functional genomics and proteomics in the clinical neurosciences: data mining and bioinformatics.
Phan JH; Quo CF; Wang MD
Prog Brain Res; 2006; 158():83-108. PubMed ID: 17027692
[TBL] [Abstract][Full Text] [Related]
17. Identifying novel prostate cancer associated pathways based on integrative microarray data analysis.
Wang Y; Chen J; Li Q; Wang H; Liu G; Jing Q; Shen B
Comput Biol Chem; 2011 Jun; 35(3):151-8. PubMed ID: 21704261
[TBL] [Abstract][Full Text] [Related]
18. Clinical proteomics: searching for better tumour markers with SELDI-TOF mass spectrometry.
Engwegen JY; Gast MC; Schellens JH; Beijnen JH
Trends Pharmacol Sci; 2006 May; 27(5):251-9. PubMed ID: 16600386
[TBL] [Abstract][Full Text] [Related]
19. Analysis of prostate cancer by proteomics using tissue specimens.
Liu AY; Zhang H; Sorensen CM; Diamond DL
J Urol; 2005 Jan; 173(1):73-8. PubMed ID: 15592032
[TBL] [Abstract][Full Text] [Related]
20. The ProteinChip Biomarker System from Ciphergen Biosystems: a novel proteomics platform for rapid biomarker discovery and validation.
Chapman K
Biochem Soc Trans; 2002 Apr; 30(2):82-7. PubMed ID: 12023830
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
